Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer

Inclusion Criteria:

* Histologically documented diagnosis of ovarian cancer, primary peritoneal carcinomatosis or fallopian tube cancer·
* Immunohistochemical documentation of c-Kit or PDGFR expression by tumor
* At least one measurable site of disease as defined by RECIST or evidence of disease progression by CA125 measurement
* Platinum-refractory or platinum-resistant

Exclusion Criteria:

* No prior exposure to imatinib (Gleevec®) as single agent or in combination
* No chemotherapy within 28 days (42 days for nitrosourea or mitomycin-C) prior to being registered to protocol therapy.
* No prior radiotherapy to ³ 25 % of the bone marrow
* No known brain metastases.
* Negative pregnancy test
* No current breastfeeding
* No investigational agents within 28 days prior to protocol therapy
* No prior malignancy in the past 5 years unless the other primary malignancy is not currently clinically significant, nor requiring active intervention, or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ
* No severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, chronic renal disease, or active uncontrolled infection)
* No known diagnosis of human immunodeficiency virus (HIV) infection.
* No major surgery within 28 days prior to being registered to protocol therapy.
* No refractory ascites requiring drainage more frequently than once a month
* No presence of clinically significant small bowel obstruction
* No prior exposure to docetaxel (exposure to paclitaxel is allowed)
* No parenteral nutrition within 28 days prior to being registered to protocol therapy.
* No concomitant treatment with potent CYP 3A4 inhibitors (i.e., ketoconazole) is permitted during therapy on this protocol.
* No therapeutic anticoagulation with warfarin while on study (use of low molecular weight heparin is allowed, if necessary).
* No peripheral neuropathy \> grade 1
* No history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80.
* No serious concomitant systemic disorders incompatible with the study
* No prior malignancies with the exception of curatively treated basal or squamous carcinoma of the skin, carcinoma in-situ of the cervix, or any other cancer for which the patient has been disease-free for \< 5 years.